DRONTAL PLUS TABLETS

Maa: Irlanti

Kieli: englanti

Lähde: HPRA (Health Products Regulatory Authority)

Osta se nyt

Valmisteyhteenveto Valmisteyhteenveto (SPC)
13-05-2017

Aktiivinen ainesosa:

PRAZIQUANTEL PH. EUR., PYRANTEL EMBONATE, FEBANTEL

Saatavilla:

Bayer Limited

ATC-koodi:

QP52AA51

INN (Kansainvälinen yleisnimi):

PRAZIQUANTEL PH. EUR., PYRANTEL EMBONATE, FEBANTEL

Annos:

Milligram

Lääkemuoto:

Tablets

Prescription tyyppi:

CAM-Companion Animal Medicine

Terapeuttinen ryhmä:

Canine

Terapeuttinen alue:

Praziquantel, combinations

Käyttöaiheet:

Endoparasiticide

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

1990-10-12

Valmisteyhteenveto

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Drontal Plus Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Tablet
Pale yellow.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the control of the following gastrointestinal tapeworms and
roundworms in dogs and puppies.
Ascarids:
_Toxocara canis, Toxascaris leonina_ (adult and late immature forms).
Hookworms:
_Uncinaria stenocephala, Ancylostoma caninum_ (adults)
Whipworms:
_Trichuris vulpis_ (adults)
Tapeworms:
_Echinococcus spp., Taenia spp., Dipylidium caninum_ (adult and
immature forms)
4.3 CONTRAINDICATIONS
Do not use simultaneously with piperazine compounds.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
As a precautionary measure to prevent establishment of_ Echinococcus
multilocularis_ in the UK and Ireland it is
recommended that all dogs and cats entering the country be treated
with praziquantel.
Fleas serve as intermediate hosts for one common type of
tapeworm-_Dipylidium caninum_. Tapeworm infestation is
certain to re-occur unless control of intermediate hosts such as
fleas, mice etc is undertaken.
ACTIVE SUBSTANCES
MG PER TABLET
Febantel
150
Pyrantel embonate
144
Praziquantel
50
For a full list of excipients, see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_8_
_/_
_0_
_4_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_6_
_6_
_2_
_4_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4
                                
                                Lue koko asiakirja
                                
                            

Näytä asiakirjojen historia